Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease

被引：11

作者：

Nguyen G.C. ^{[1
]}

Harris M.L. ^{[1
]}

Dassopoulos T. ^{[1
]}

机构：

[1] Division of Gastroenterology, The Johns Hopkins Hospital, Baltimore, MD 21287

来源：

Current Gastroenterology Reports | 2006年 / 8卷 / 6期

关键词：

Ulcerative Colitis; Tacrolimus; Thiopurine; Mesalamine; TPMT Activity;

D O I：

10.1007/s11894-006-0040-6

中图分类号：

学科分类号：

摘要：

Immunomodulators are a class of drugs that attenuate the underlying inflammatory processes of Crohn's disease (CD) and ulcerative colitis (UC), the two major inflammatory bowel diseases (IBD). These agents play a prominent role in the management of refractory and steroid-dependent IBD. The immunomodulatory drugs in the IBD arsenal include azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, and tacrolimus. Azathioprine and 6-mercaptopurine are considered first-line immunosuppressants due to their proven efficacy in both CD and UC and their safety profile, whereas cyclosporine occupies a niche as a surgery-sparing agent in the acute management of severe, steroid-refractory UC. Immunomodulators also appear to have a role as adjunctive therapy when used with infliximab or other biologic agents to reduce immunogenicity. Although data have been limited to observational studies, azathioprine and 6-mercaptopurine may be used during pregnancy. Copyright © 2006 by Current Science Inc.

引用

页码：499 / 505

页数：6

共 53 条

[1]

D'Haens G.R., Hommes D., Baert F., Et al., A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease, Gastroenterology, 130, (2006)

[2]

Hommes D., Baert F., van Assche G., Et al., The ideal management of Crohn's disease: Top down versus step up strategies, a randomized controlled trial, Gastroenterology, 130, (2006)

[3]

Poppe D., Tiede I., Fritz G., Et al., Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins, J Immunol, 176, pp. 640-651, (2006)

[4]

Lichtenstein G.R., Abreu M.T., Cohen R., Et al., American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease, Gastroenterology, 130, pp. 940-987, (2006)

[5]

Ardizzone S., Maconi G., Russo A., Et al., Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis, Gut, 55, pp. 47-53, (2006)

[6]

Hanauer S.B., Korelitz B.I., Rutgeerts P., Et al., Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: A 2-year trial, Gastroenterology, 127, pp. 723-729, (2004)

[7]

Ardizzone S., Maconi G., Sampietro G.M., Et al., Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease, Gastroenterology, 127, pp. 730-740, (2004)

[8]

Cosnes J., Nion-Larmurier I., Beaugerie L., Et al., Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery, Gut, 54, pp. 237-241, (2005)

[9]

Dubinsky M.C., Azathioprine, 6-mercaptopurine in inflammatory bowel disease: Pharmacology, efficacy, and safety, Clin Gastroenterol Hepatol, 2, pp. 31-743, (2004)

[10]

Lichtenstein G.R., Abreu M.T., Cohen R., Et al., American Gastroenterological Association Institute medical position statement on cortico steroids, immunomodulators, and infliximab in inflammatory bowel disease, Gastroenterology, 130, pp. 935-939, (2006)

← 1 2 3 4 5 6 →